Chatbots beat doctors on paper. Then real patients used them and it fell apart.

Run time: 6:50

In today's episode:

1. Chatbot answers rated more empathetic than doctors, preferred 79% of the time
2. GPT-4 alone beat physicians by ~15 points on diagnostic vignettes
3. Google's AMIE matched or beat primary care docs in text consultations
4. Microsoft's system solved 85% of hard NEJM cases vs doctors' 20%
5. Oxford RCT: patients using LLMs did no better than a web search
6. Half of consumer chatbot medical advice carried potential for harm
7. ~1 in 6 US adults now use an AI chatbot for health advice monthly

TL;DR:

• On clean written cases, AI genuinely out-diagnoses doctors — that part is peer-reviewed, not hype.
• On real patients doing their own typing, that edge vanishes: an Oxford RCT (~1,300 people) found LLM users did no better than web search, because patients omit the detail that matters and models mix right advice with wrong.
• What's actually deployed is the opposite of a doctor replacement: clinician tools like OpenEvidence (used by ~65% of US doctors) keep a licensed human between the model and the prescription. No LLM is FDA-cleared to diagnose you solo.

Sources cited:

• JAMA Internal Medicine, Ayers et al.
• JAMA Network Open, Goh et al.
• Nature, Google DeepMind
• Microsoft AI
• Oxford, Nuffield Dept of Primary Care (Payne et al.)
• NBC News on OpenEvidence

Subscribe: YouTube

medAI Times is for educational and informational purposes only. The content does not constitute medical advice, diagnosis, treatment recommendation, or professional clinical guidance. Consult qualified healthcare professionals and refer to official sources before making clinical, research, regulatory, or business decisions.

Three hundred million health questions a week. Chat G P T just opened the doors.

Run time: 7:11

In today's episode:

1. ChatGPT Health opens to every US adult
2. FDA lets Dexcom skip part of premarket review
3. White House starts clinical AI benchmarking sprint
4. Nature Medicine RCT: eye AI lifts diagnosis
5. Utah publishes AI prescription renewal data
6. Medtronic clears real-time AI for surgery
7. Tempus buys Personalis for $1.5 billion
8. Epic's AI leader joins an executive exodus
9. AMD invests up to $5 billion in Anthropic
10. Anthropic opens rare-disease research grants
11. OpenAI's test models breached Hugging Face
12. Google ships Gemini 3.6 Flash, still no 3.5 Pro

TL;DR:

• ChatGPT Health is now open to every US adult on every plan, connected to Epic and Oracle Health records, at 300 million health queries a week — with zero outcome evidence and a fresh lawsuit.
• Washington moved twice in one week: the FDA gave Dexcom the first premarket exemption under its TEMPO pilot in exchange for Medicare-generated real-world evidence, while OSTP, FDA and ONC opened a one-month sprint to define how clinical AI should be evaluated at all.
• The week's only top-tier randomized trial (Nature Medicine, July 24) worked because a clinician stayed in the loop: AI-assisted top-5 genetic accuracy 88.5% vs 67.3% for controls in inherited retinal disease.

Sources cited:

• TechCrunch
• MedTech Dive
• STAT
• Nature Medicine
• Forbes
• Medtronic
• MedCity News
• STAT
• AMD/GlobeNewswire
• Anthropic

Subscribe: YouTube

medAI Times is for educational and informational purposes only. The content does not constitute medical advice, diagnosis, treatment recommendation, or professional clinical guidance. Consult qualified healthcare professionals and refer to official sources before making clinical, research, regulatory, or business decisions.

Two hundred million protein shapes, one Nobel Prize, and still zero A I drugs approved.

Run time: 6:32

In today's episode:

1. AlphaFold two hit ~90/100 accuracy at CASP14 (2020)
2. Database now covers 214M+ protein sequences, 3M+ users
3. 2024 Nobel Prize: Hassabis, Jumper (AlphaFold) + Baker (design)
4. AlphaFold3 predicts drug-protein binding, 58% vs 24% docking
5. Static shapes only — fails on flexible, shape-shifting targets
6. Zero AlphaFold-designed drugs approved; first trials targeted end-2026

TL;DR:

• Real, at the research layer: AlphaFold solved a 50-year protein-shape problem (peer-reviewed, Nobel-confirmed) and put 214M+ free structures in front of 3M+ scientists in ~190 countries — it changed how medical research begins.
• Not yet, at the clinic: No AlphaFold-designed drug is approved or, as of spring 2026, even dosed in a patient; the models predict one static shape and stumble on the flexible drug targets that matter most.
• The milestone to watch: Isomorphic Labs (DeepMind spinout, $2.1B Series B) targets its first human cancer trials by end-2026 — that first-dose event, not the Nobel, is where "changed medicine" gets tested against outcome evidence.

Sources cited:

• Nature 2021, Jumper et al.
• Nucleic Acids Research 2024, Varadi et al.
• Nature 2024, Abramson et al.
• EMBL-EBI resource update
• PMC 2025, anti-schistosomal docking pipeline
• bioRxiv 2025, AlphaFold3 in Drug Discovery: capabilities & limitations
• Isomorphic Labs, $2.1B Series B (May 2026)
• NobelPrize.org, Chemistry 2024

Subscribe: YouTube

medAI Times is for educational and informational purposes only. The content does not constitute medical advice, diagnosis, treatment recommendation, or professional clinical guidance. Consult qualified healthcare professionals and refer to official sources before making clinical, research, regulatory, or business decisions.